Clinical Trial Update: Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study [Phase 4]

View source ↗

Summary

A Phase 4 GI tolerability study of deferasirox in patients with myelodysplastic syndrome and transfusional iron overload conducted by Novartis was terminated; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Transfusional Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome, Transfusional Iron Overload | Phase 4 | Status: TERMINATED | Results posted: 2013-11-15